Clinical outcomes and emergence of resistance of <i>Pseudomonas aeruginosa</i> infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.

ABSTRACT: Few studies compare outcomes of patients with difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. A multicenter prospective study was conducted of unique patients with DTR P. aeruginosa infections from 2018 to 2023 receiving >72 h of ceftolozane-tazobactam or ceftazidime-avibactam, with confirmation that the P. aeruginosa isolate was susceptible to the agent administered by broth microdilution. Inverse probability weighting (IPW) incorporating propensity scores was utilized to ensure balanced baseline characteristics. Regression performed on the post-IPW group determined 30-day mortality and subsequent emergence of resistance (i.e., ≥4-fold increase in MIC) to the initial treatment (i.e

SUBMITTER: Hareza DA 

PROVIDER: S-EPMC11459953 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature